CompanyGraph
Shantou Institute of Ultrasonic Instruments Co., Ltd.
301602 · SZSE · China
siui.com.cnFinancials as of FY2025
What stands out
- Valued far above the size of its business
At a glance
- Depends onMidstream position: 6 outgoing, 8 incoming connections
- ScaleMarket cap is $1.15B, above the global median of $1.15B
- PositionProfit margin is 31.8%, higher than 95% of its Medical Devices peers (median 4.8%)
- Interpretations9 currently firing — 9
Sign in to view price data.
Sign inWhat the company actually pays, and whether its own cash supports it.
Dividends view
Yield
0.81%
Annual Rate
CNY 0.15Paid annual
Payout Ratio
37.8%Sustainable
Last Ex-Dividend
Jun 24, 2026
The reported statements, read against the company's own industry.
What stands out
- Valued far above the size of its business
Financials view
Market Capitalization
7.77BCNY1.15B · vs all stocks (USD)
Trailing P/E
67.15xvs Medical Devices peers
Revenue (TTM)
373.41MCNY55.46M · vs all stocks (USD)
Profit Margin
31.79%vs Medical Devices peers
52-Week Change
-33.33%vs all stocks
Market Capitalization
7.77BCNY1.15B · vs all stocks (USD)
Enterprise Value
6.44BCNY956.85M · vs all stocks (USD)
Trailing P/E
67.15xvs Medical Devices peers
Price to Sales (TTM)
20.80xvs Medical Devices peers
Price to Book (MRQ)
5.67xvs Medical Devices peers
Enterprise to Revenue
17.25xvs Medical Devices peers
Enterprise to EBITDA
48.81xvs Medical Devices peers
Gross Margin
69.56%vs Medical Devices peers
Profit Margin
31.79%vs Medical Devices peers
Operating Margin
20.99%vs Medical Devices peers
Return on Assets (TTM)
5.19%vs Medical Devices peers
Return on Equity (TTM)
8.92%vs Medical Devices peers
Revenue (TTM)
373.41MCNY55.46M · vs all stocks (USD)
Revenue per Share (TTM)
0.8460CNYUpdated Aug 20, 2026Quarterly Revenue Growth
-32.60%vs Medical Devices peers
Gross Profit (TTM)
261.45MCNY38.83M · vs all stocks (USD)
EBITDA (TTM)
150.07MCNY22.29M · vs all stocks (USD)
Net Income (TTM)
118.72MCNY17.63M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
-76.80%vs Medical Devices peers
Operating Cash Flow (TTM)
126.88MCNY18.84M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
56.70MCNY8.42M · vs all stocks (USD)
Trailing Annual Dividend Rate
0.1500CNYUpdated Aug 20, 2026Trailing Annual Dividend Yield
0.81%vs all stocks
Payout Ratio
37.78%vs Medical Devices peers
Revenue
405.51MCNYFY2025 · Dec 31, 2025Cost of Goods Sold
115.38MCNYFY2025 · Dec 31, 2025Gross Profit
290.13MCNYFY2025 · Dec 31, 2025Operating Income
155.97MCNY23.16M · vs all stocks (USD)
Pre-tax Income
170.21MCNYFY2025 · Dec 31, 2025Income Tax Expense
21.29MCNYFY2025 · Dec 31, 2025Net Income
148.92MCNYFY2025 · Dec 31, 2025EBIT
155.97MCNYFY2025 · Dec 31, 2025EBITDA (Income Statement)
169.58MCNYFY2025 · Dec 31, 2025Research & Development
50.14MCNYFY2025 · Dec 31, 2025Selling, General & Administrative
31.56MCNYFY2025 · Dec 31, 2025Other Operating Expenses
4.53MCNYFY2025 · Dec 31, 2025Non-operating Interest Income
27.14MCNYFY2025 · Dec 31, 2025EPS (Basic)
0.3500CNYFY2025 · Dec 31, 2025EPS (Diluted)
0.3500CNYFY2025 · Dec 31, 2025Basic Shares Outstanding
425.49MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
425.49MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
148.92MCNYFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025Operating Cash Flow
129.70MCNYFY2025 · Dec 31, 2025Free Cash Flow
114.50MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
392.52MCNYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
148.92MCNYFY2025 · Dec 31, 2025Other Non-cash Items
1.52MCNYFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
4.04MCNYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-24.78MCNYFY2025 · Dec 31, 2025Capital Expenditures
-15.20MCNYFY2025 · Dec 31, 2025Purchase of Investments
-2.35BCNYFY2025 · Dec 31, 2025Sale of Investments
2.09BCNYFY2025 · Dec 31, 2025Net Investing Cash Flow
-282.46MCNYFY2025 · Dec 31, 2025Common Dividends Paid
-43.69MCNYFY2025 · Dec 31, 2025Other Financing Charges
384.98MCNYFY2025 · Dec 31, 2025Net Financing Cash Flow
341.29MCNYFY2025 · Dec 31, 2025Shares Outstanding
428.33MSharesUpdated Aug 20, 2026Float Shares
75.13MSharesUpdated Aug 20, 2026% Held by Insiders
82.91%vs all stocks
% Held by Institutions
3.89%vs all stocks
Total Cash (MRQ)
1.18BCNY175.50M · vs all stocks (USD)
Total Cash per Share (MRQ)
2.76CNYUpdated Aug 20, 2026Total Debt (MRQ)
0.00CNYvs all stocks (USD)
Total Debt to Equity (MRQ)
0.00xvs Medical Devices peers
Current Ratio (MRQ)
12.86xvs Medical Devices peers
Book Value per Share (MRQ)
3.20CNYUpdated Aug 20, 2026Total Assets
1.49BCNY220.95M · vs all stocks (USD)
Total Current Assets
1.36BCNYFY2025 · Dec 31, 2025Total Liabilities
126.87MCNYFY2025 · Dec 31, 2025Total Non-current Assets
125.96MCNYFY2025 · Dec 31, 2025Total Non-current Liabilities
9.65MCNYFY2025 · Dec 31, 2025Total Current Liabilities
117.23MCNYFY2025 · Dec 31, 2025Cash
959.32MCNYFY2025 · Dec 31, 2025Cash Equivalents
210.99MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents
1.17BCNYFY2025 · Dec 31, 2025Accounts Receivable
44.65MCNYFY2025 · Dec 31, 2025Inventory
135.86MCNYFY2025 · Dec 31, 2025Accounts Payable
23.41MCNYFY2025 · Dec 31, 2025Other Current Liabilities
760.15KCNYFY2025 · Dec 31, 2025Other Non-current Liabilities
7.29MCNYFY2025 · Dec 31, 2025Common Stock (Book)
428.33MCNYFY2025 · Dec 31, 2025Retained Earnings
537.56MCNYFY2025 · Dec 31, 2025Total Shareholders' Equity
1.36BCNY202.11M · vs all stocks (USD)
52-Week Low
13.40CNYUpdated Aug 20, 202652-Week High
28.40CNYUpdated Aug 20, 202652-Week Change
-33.33%vs all stocks
50-Day MA
15.13CNYUpdated Aug 20, 2026200-Day MA
19.55CNYUpdated Aug 20, 2026Avg 10-Day Volume
11.38MSharesUpdated Aug 20, 2026Avg 30-Day Volume
5.95MSharesUpdated Aug 20, 2026Diluted EPS (TTM)
0.2700CNYUpdated Aug 20, 20269 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company financially stable?
Cash Elevated Relative to Current Liabilities and Total Assets
Its cash covers more of its near-term bills than in its industry, and is a large share of everything it owns.
Reads
Liquidity Ratios Elevated
It can cover near-term bills from cash alone, not just from inventory.
Reads
How does this company use capital?
Cash-Flow Ratios Elevated
More of its sales turn into cash than in its industry, and less of that cash is consumed by reinvestment than at most of its peers.
Reads
Three Margin Ratios Elevated Across Gross, Operating, And Cash-Conversion Levels
Its gross margin and its cash margin are high for its industry, and its operating margin is high outright.
Reads
Industry-Benchmarked ROA and Margin Elevated
Returns and margins have sat in the top of its industry across five years.
Reads
Three Margin Ratios Elevated Across Gross, Operating, And Net Levels
Its gross and net margins are high for its industry, and its operating margin is high outright.
Reads
How is this stock valued?
High Retained Earnings With Profitability And Equity
Profits kept in the business fund much of what it owns, after five straight profitable years.
Reads
Price Below Mean With Profitability And Book Value
Price sits well below its yearly mean, on three profitable years and rising book value.
Reads
Price Below Mean With Profitability And Equity
Price sits well below its yearly mean, profitable three years, and its equity ratio is high for its industry.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Profit margin is 31.8%, higher than 95% of its Medical Devices peers (median 4.8%)Significant
Profit margin: 0.32Industry median: 0.05Industry P95: 0.32Peers compared: 102
Current ratio is 12.86×, higher than 95% of its Medical Devices peers (median 3.83×)Significant
Current ratio: 12.86Industry median: 3.83Industry P95: 12.54Peers compared: 102
Debt-to-equity is 0×, lower than 95% of its Medical Devices peers (median 0.11×)Notable
Debt-to-equity: 0.00Industry median: 0.11Industry P5: 0.00Peers compared: 102
Structural Tensions
Valued far above the size of its businessSignificant
Price-to-Sales: 20.80Revenue Growth YoY: -0.33
Financial Health
High earnings qualityNotable
Earnings Quality Score: 0.62
High structural barrier to entryNotable
Barrier to Entry: 0.58
Supply Chain
Midstream position: 6 outgoing, 8 incoming connectionsNotable
Outgoing: 6.00Incoming: 8.00
High connectivity hub: 14 industry connectionsNotable
Total Connections: 14.00
Scale
Market cap is $1.15B, above the global median of $1.15BNotable
Market cap (USD): 1,153,349,338.223Global Median: 1,146,734,693.424
Companies that share the same coordination system — how they create, deliver, or capture value.
MeiraGTx Holdings plc
Tier 1ProductionApproval-Gated PipelineRuleRisk
Zhejiang Tianyu Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Eton Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRule
Sino Medical Sciences Technology Inc.
Tier 1ProductionApproval-Gated PipelineRule
Innovita Biological Technology Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
BioGaia AB
Tier 1ProductionApproval-Gated PipelineRuleFlow
Sanofi Consumer Healthcare Inc.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Northeast Pharmaceutical Group Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Alvotech S.A.
Tier 1ProductionApproval-Gated PipelineRule
Guilin Sanjin Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
Hangzhou Sunrise Technology Co., Ltd.
9 interpretationsThree Margin Ratios Elevated Across Gross, Operating, And Cash-Conversion LevelsHigh Retained Earnings With Profitability And EquityCash-Flow Ratios ElevatedCash Elevated Relative to Current Liabilities and Total AssetsLiquidity Ratios ElevatedIndustry-Benchmarked ROA and Margin ElevatedThree Margin Ratios Elevated Across Gross, Operating, And Net LevelsPrice Below Mean With Profitability And Book ValuePrice Below Mean With Profitability And Equity
Amoy Diagnostics Co., Ltd.
9 interpretationsThree Margin Ratios Elevated Across Gross, Operating, And Cash-Conversion LevelsHigh Retained Earnings With Profitability And EquityCash-Flow Ratios ElevatedCash Elevated Relative to Current Liabilities and Total AssetsLiquidity Ratios ElevatedIndustry-Benchmarked ROA and Margin ElevatedThree Margin Ratios Elevated Across Gross, Operating, And Net LevelsPrice Below Mean With Profitability And Book ValuePrice Below Mean With Profitability And Equity
Sinofibers Technology Co., Ltd.
8 interpretationsThree Margin Ratios Elevated Across Gross, Operating, And Cash-Conversion LevelsHigh Retained Earnings With Profitability And EquityCash-Flow Ratios ElevatedLiquidity Ratios ElevatedIndustry-Benchmarked ROA and Margin ElevatedThree Margin Ratios Elevated Across Gross, Operating, And Net LevelsPrice Below Mean With Profitability And Book ValuePrice Below Mean With Profitability And Equity